Cat. No. | Product name | CAS No. |
DC3164 |
BIBW2992-MA2 (Afatinib dimaleate)
Featured
Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. |
850140-73-7 |
DC10513 |
AFN-1252(Debio 1452)
Featured
AFN-1252(Debio 1452) is a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis at concentrations of ≤0.12 μg/ml. |
620175-39-5 |
DC7994 |
Afuresertib HCl
Featured
Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). |
1047645-82-8 |
DC8411 |
Afuresertib
Featured
Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2. |
1047644-62-1 |
DC8051 |
AG-120 (Ivosidenib)
Featured
AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein. |
1448347-49-6 |
DC8374 |
AG-221(Enasidenib)
Featured
AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein. |
1446502-11-9 |
DC2096 |
AG490
Featured
AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively. |
133550-30-8 |
DC10439 |
Vorasidenib (AG881)
Featured
AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2). |
1644545-52-7 |
DC3171 |
Agomelatine
Agomelatine is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. |
138112-76-2 |
DC8695 |
Akt1 and Akt2-IN-1
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity. |
893422-47-4 |
DCAPI1467 |
Alcaftadine
Alcaftadine |
147084-10-4 |
DCAPI1034 |
Alendronate (Fosamax)
Alendronate (Fosamax) |
121268-17-5 |
DC12072 |
Alflutinib (AST2818 mesylate)
Featured
Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.. |
2130958-55-1 |
DCAPI1495 |
Aliskiren Hemifumarate
Featured
Aliskiren hemifumarate(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM. |
173334-58-2 |
DC11495 |
Allitinib
Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays. |
897383-62-9 |
DC7692 |
Almorexant HCl (Act-078573)
Featured
Almorexant(ACT078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively. |
913358-93-7 |
DC10234 |
Alosetron Hydrochloride
Alosetron Hydrochloride is the hydrochloride salt form of alosetron, a potent and selective 5-HT3 receptor antagonist. |
122852-69-1 |
DC8606 |
Alvimopan monohydrate
Alvimopan(LY 246736; ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery. |
1383577-62-5 |
DC8605 |
Alvimopan dihydrate
Alvimopan(LY 246736; ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery. |
170098-38-1 |
DC11301 |
ALZ-801
Featured
ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated prodrug of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease. |
1034190-08-3 |
DC9830 |
AM-2394
Featured
AM-2394 is a potent and selective Glucokinase agonist (GKA), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. |
1442684-77-6 |
DC10372 |
Amcasertib(BBI503)
Featured
Amcasertib(BBI503) is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases. |
1129403-56-0 |